14.
First KRAS/PRMT5 combination data reports 92% ORR (t.co)
Early clinical data for a KRAS inhibitor plus PRMT5 combination suggests combinations may define the next phase of RAS-targeted cancer therapy
@RYEbright on Backlist
1 appearance on the backlist front page in the last 30 days.